DrugPatentWatch Database Preview

Osimertinib mesylate - Generic Drug Details

What are the generic sources for osimertinib mesylate and what is the scope of osimertinib mesylate patent protection?

Osimertinib mesylate is the generic ingredient in one branded drug marketed by Astrazeneca Pharms and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for osimertinib mesylate. One supplier is listed for this compound.

Summary for osimertinib mesylate

US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	35
Patent Applications:	3
DailyMed Link:	osimertinib mesylate at DailyMed

Pharmacology for osimertinib mesylate

Drug Class	Kinase Inhibitor
Mechanism of Action	Kinase Inhibitors Cytochrome P450 3A Inhibitors Cytochrome P450 3A4 Inducers Cytochrome P450 1A2 Inducers Breast Cancer Resistance Protein Inhibitors

Synonyms for osimertinib mesylate

1421373-66-1
2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-, methanesulfonate (1:1)
AK198680
AKOS026673944
AZD 9291 mesylate
AZD-9291 (Mesylate)
AZD-9291 mesylate
AZD-9291 mesylate pound Osimertinib Mereletinib)
AZD9291 mesylate
AZD9291 Ms salt, Osimertinib Ms salt; Mereletinib Ms salt
BC600811
CHEBI:90948
CHEMBL3545063
D10766
EX-A1577
FT-0699962
HY-15772A
KS-00000SU8
Mereletinib mesylate
MFCD28137994
MolPort-044-560-736
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide methanesulfonate
N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide methanesulfonate
Osimertinib mesilate (JAN)
Osimertinib mesylate (USAN)
Osimertinib mesylate [USAN]
osimertinib methanesulfonate
osimertinib monomesylate
RDL94R2A16
SCHEMBL14661152
Tagrisso (TN)
UNII-RDL94R2A16

US Patents and Regulatory Information for osimertinib mesylate

+ Get email alerts for changes to this table

Glossary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Pharms	TAGRISSO	osimertinib mesylate	TABLET;ORAL	208065-001	Nov 13, 2015		RX	Yes	No	➤ Sign Up	➤ Sign Up	Y	Y		➤ Sign Up
Astrazeneca Pharms	TAGRISSO	osimertinib mesylate	TABLET;ORAL	208065-002	Nov 13, 2015		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y	Y		➤ Sign Up
Astrazeneca Pharms	TAGRISSO	osimertinib mesylate	TABLET;ORAL	208065-001	Nov 13, 2015		RX	Yes	No	➤ Sign Up	➤ Sign Up				➤ Sign Up
Astrazeneca Pharms	TAGRISSO	osimertinib mesylate	TABLET;ORAL	208065-002	Nov 13, 2015		RX	Yes	Yes	➤ Sign Up	➤ Sign Up				➤ Sign Up
Astrazeneca Pharms	TAGRISSO	osimertinib mesylate	TABLET;ORAL	208065-002	Nov 13, 2015		RX	Yes	Yes	➤ Sign Up	➤ Sign Up				➤ Sign Up
Astrazeneca Pharms	TAGRISSO	osimertinib mesylate	TABLET;ORAL	208065-001	Nov 13, 2015		RX	Yes	No	➤ Sign Up	➤ Sign Up				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

International Patents for osimertinib mesylate

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Country	Document Number	Estimated Expiration
Costa Rica	20130629	➤ Sign Up
Hong Kong	1192549	➤ Sign Up
Taiwan	201319057	➤ Sign Up
Canada	2881987	➤ Sign Up
Eurasian Patent Organization	201690328	➤ Sign Up
Singapore	10201402860Q	➤ Sign Up
Country	Document Number	Estimated Expiration